Navigation Links
Pharmacyclics Reports First Quarter 2013 Results
Date:5/1/2013

ressions are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to us and are subject to a number of risks, uncertainties and other factors that could cause our actual results, performance, expected liquidity or achievements to differ materially from those projected in, or implied by, these forward-looking statements. Factors that may cause such a difference include, without limitation, our need for substantial additional financing and the availability and terms of any such financing, the safety and/or efficacy results of clinical trials of our product candidates, our failure to obtain regulatory approvals or comply with ongoing governmental regulation, our ability to commercialize, manufacture and achieve market acceptance of any of our product candidates, for which we rely heavily on collaboration with third parties, and our ability to protect and enforce our intellectual property rights and to operate without infringing upon the proprietary rights of third parties. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, performance or achievements and no assurance can be given that the actual results will be consistent with these forward-looking statements. For more information about the risks and uncertainties that may affect our results, please see the Risk Factors section of our filings with the Securities and Exchange Commission, including our transition report on Form 10-K for the six month period ended December 31, 2012 and quarterly reports on Form 10-Q. We do not intend to update any of the forward-looking statements after the date of this announcement to conform these statements to actual results, to changes in management's expectations or otherwise, except as may be required by law.

 Pharmacyclics, Inc.Condensed Consolidated Balance Sheets(unaudited; in thousands)Mar. 31,Dec. 31,20
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
2. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
3. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
4. Pharmacyclics, Inc. Prices Public Offering of Common Stock
5. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
6. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
7. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
8. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
9. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
10. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
11. Hospira Reports First-Quarter 2013 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 Patient engagement has ... consequently, organizations are turning to an assortment of ... As part of this evolving approach to patient ... communicate and engage patients throughout their experiences with ... empowerment. By mapping the patient journey and employing ...
(Date:7/11/2014)... July 11, 2014 According ... by Composition of Material, Application (Healthcare, Homeland security, ... Product (Personal Instrument, Hand-Held Instruments, Fixed, and Installed ... to 2013 - 2020", published by MarketsandMarkets, the Scintillator Market ... 5.62% from 2014 to 2020, and reach $479.16 ...
(Date:7/11/2014)... -- On Thursday, July 10, 2014, ... Jones Industrial Average finished the day 0.42% lower at 16,915.07, ... losses were broad based as eight out of ten sectors ... Sector Index ended the day at 711.88, down 0.02%, while ... Investor-Edge has initiated coverage on the following equities: Covidien PLC ...
Breaking Medicine Technology:New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2Scintillator Market will be worth $479.16 Million by 2020 2Scintillator Market will be worth $479.16 Million by 2020 3Scintillator Market will be worth $479.16 Million by 2020 4Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4
... Inc. today announced that data from a Phase 1/2 study, ... Proceedings of the National Academy of Sciences, demonstrate the ... action human growth hormone, compared to therapy with native hormone. ... treated with ARX201, which was generated with Ambrx,s ReCODE™ technology. ...
... Korea, May 25, 2011 New findings presented from ... program showed that the safety profile of STELARA and ... time in adults with moderate to severe plaque psoriasis ... reported findings from an analysis of four placebo-controlled Phase ...
Cached Medicine Technology:Proceedings of the National Academy of Sciences Report Superiority of Human Growth Hormone Generated with Ambrx Technology 2New Four Year STELARA® Data Show Consistent Safety Profile Over Time in Patients With Moderate to Severe Plaque Psoriasis 2New Four Year STELARA® Data Show Consistent Safety Profile Over Time in Patients With Moderate to Severe Plaque Psoriasis 3New Four Year STELARA® Data Show Consistent Safety Profile Over Time in Patients With Moderate to Severe Plaque Psoriasis 4New Four Year STELARA® Data Show Consistent Safety Profile Over Time in Patients With Moderate to Severe Plaque Psoriasis 5New Four Year STELARA® Data Show Consistent Safety Profile Over Time in Patients With Moderate to Severe Plaque Psoriasis 6New Four Year STELARA® Data Show Consistent Safety Profile Over Time in Patients With Moderate to Severe Plaque Psoriasis 7New Four Year STELARA® Data Show Consistent Safety Profile Over Time in Patients With Moderate to Severe Plaque Psoriasis 8New Four Year STELARA® Data Show Consistent Safety Profile Over Time in Patients With Moderate to Severe Plaque Psoriasis 9New Four Year STELARA® Data Show Consistent Safety Profile Over Time in Patients With Moderate to Severe Plaque Psoriasis 10New Four Year STELARA® Data Show Consistent Safety Profile Over Time in Patients With Moderate to Severe Plaque Psoriasis 11
(Date:7/12/2014)... July 12, 2014 Sean Francis, owner of the ... special challenges to his clients. He’s also known for his support ... found a way to combine the two and is excited to ... for the Boys and Girls Club. , The funds are the ... on June 23rd. Francis sent out emails and asked his clients ...
(Date:7/12/2014)... 12, 2014 Using and carrying around ... two inventors from Ashland, Va., decided that there needed ... inspired us to conceive of our design," he said. ... KIDNEY KOVER, which provides an inconspicuous way to use ... as well as promotes comfort and peace of mind. ...
(Date:7/12/2014)... With prom shopping reaching its final days, VogueQueen.com, a ... showcase its new and trendy apparels. Recently, the company ... its online shop. Additionally, it is now providing huge ... According to the company’s sales manager, the promotion will ... , He says, “Now, worldwide clients can order cheap ...
(Date:7/12/2014)... Wright & Schulte LLC has filed a ... subsidiary of Johnson & Johnson, on behalf of an Ohio ... a metal-on-metal DePuy Pinnacle hip replacement and had to undergo ... implant. The DePuy hip lawsuit was filed July 7, 2014, ... No. 3:14-cv-2427) where DePuy Pinnacle Hip lawsuit litigation is ...
(Date:7/12/2014)... 12, 2014 Doylestown Hospital recently conducted ... of men’s health questions. Paddock tackles topics including ... why women live longer than men, and testosterone replacement ... Made Simple featured on Doylestown Hospital’s website, Dr. ... at any age. If you notice pain, bulging, or ...
Breaking Medicine News(10 mins):Health News:Kawartha Lakes Fit Body Boot Camp’s Successful Fat Loss Challenge Results in $2,000 to Boys and Girls Club 2Health News:Kawartha Lakes Fit Body Boot Camp’s Successful Fat Loss Challenge Results in $2,000 to Boys and Girls Club 3Health News:VogueQueen.com Updates Its Summer Collection With New And Trendy Evening Dresses 2Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 2Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 3Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 4Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 5Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2
... of scientists, led by H. Lundbeck A/S and King,s ... research academic-industry collaboration projects to find new methods for ... Novel Methods leading to New Medications in Depression ... top scientists from academic institutions with a wide range ...
... onPoint ... to announce that Joe Baffone, an 18-year oncology executive with Sanofi-Aventis has joined onPoint ... ... full service healthcare data solutions and reimbursement analytics firm, is proud to announce that ...
... , ... TBT Payment Acceptance Solutions offers merchant services across the southeast such as credit ... and loyalty cards. ,Whether you are a merchant in need of a payment ... with an established and trusted company, www.tbtpas.com allows for convenient access ...
... ... company CTW, Inc. of Mississippi and Massachusetts-based medical device manufacturer Tegra Medical to join ... ... private equity firm based in Boston, MA, is pleased to announce its majority investment ...
... , INDIANAPOLIS , Jan. ... solutions, has announced the completion of its $8 million ... Menlo Park, California .  The funding will allow Orbis ... and, in turn, help alleviate the nation,s wide-spread nursing shortages. ...
... , PORT-AU-PRINCE, Haiti , Jan. 19 , ... death toll likely well over 100,000 3 million people displaced or ... quake: 4 to 4.5 million) , Conditions in ... the quake are now scattered across 243 different locations in Port-au-Prince ...
Cached Medicine News:Health News:Largest academic-industry collaboration for drug discovery in depression and schizophrenia launched 2Health News:Largest academic-industry collaboration for drug discovery in depression and schizophrenia launched 3Health News:Oncology Industry Veteran, Joe Baffone, Joins onPoint Oncology, LLC. 2Health News:TBT Payment Acceptance Solutions Announces Launch of Redesigned “User-Friendly” Website, www.tbtpas.com 2Health News:Riverside Partners Announces Acquisition of CTW, Inc. and Partnership with Tegra Medical 2Health News:Riverside Partners Announces Acquisition of CTW, Inc. and Partnership with Tegra Medical 3Health News:Riverside Partners Announces Acquisition of CTW, Inc. and Partnership with Tegra Medical 4Health News:Orbis Education Secures $8.0 Million in Funding for Expanding Online Nursing Education Platform 2Health News:Orbis Education Secures $8.0 Million in Funding for Expanding Online Nursing Education Platform 3Health News:Orbis Education Secures $8.0 Million in Funding for Expanding Online Nursing Education Platform 4Health News:World Vision Situation Update: More Aid Reaching Many Survivors, but Conditions Remain Dire 2Health News:World Vision Situation Update: More Aid Reaching Many Survivors, but Conditions Remain Dire 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: